EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

M Solh, NJ Bahlis, NS Raje, CL Costello, B Dholaria, MY Levy, MH Tomasson, H Dube, MA Damore, HK Lon, C Basu, A Skoura, EM Chan, S Trudel, A Jakubowiak, MP Chu, C Gasparetto, A Dalovisio, M Sebag, AM Lesokhin

Open source

DOI: 10.1016/j.htct.2021.10.331
Published: 10
Container: Hematology, Transfusion and Cell Therapy
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.htct.2021.10.331,
  title = {EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA},
  author = {M Solh and NJ Bahlis and NS Raje and CL Costello and B Dholaria and MY Levy and MH Tomasson and H Dube and MA Damore and HK Lon and C Basu and A Skoura and EM Chan and S Trudel and A Jakubowiak and MP Chu and C Gasparetto and A Dalovisio and M Sebag and AM Lesokhin},
  year = {2021},
  journal = {Hematology, Transfusion and Cell Therapy},
  doi = {10.1016/j.htct.2021.10.331},
  url = {https://doi.org/10.1016/j.htct.2021.10.331}
}

RIS

TY  - JOUR
TI  - EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
AU  - M Solh
AU  - NJ Bahlis
AU  - NS Raje
AU  - CL Costello
AU  - B Dholaria
AU  - MY Levy
AU  - MH Tomasson
AU  - H Dube
AU  - MA Damore
AU  - HK Lon
AU  - C Basu
AU  - A Skoura
AU  - EM Chan
AU  - S Trudel
AU  - A Jakubowiak
AU  - MP Chu
AU  - C Gasparetto
AU  - A Dalovisio
AU  - M Sebag
AU  - AM Lesokhin
PY  - 2021
JO  - Hematology, Transfusion and Cell Therapy
DO  - 10.1016/j.htct.2021.10.331
UR  - https://doi.org/10.1016/j.htct.2021.10.331
ER  -

APA

Solh, M., Bahlis, N., Raje, N., Costello, C., Dholaria, B., Levy, M., Tomasson, M., Dube, H., Damore, M., Lon, H., Basu, C., Skoura, A., Chan, E., Trudel, S., Jakubowiak, A., Chu, M., Gasparetto, C., Dalovisio, A., Sebag, M., & Lesokhin, A. (2021). EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. Hematology, Transfusion and Cell Therapy. https://doi.org/10.1016/j.htct.2021.10.331

Source records

doaj · retrieved 2026-09-26T22:30:09.165Z